RxDoctor Payments Data

Beatriz Garza de Caldera, MD

Family Medicine · Laredo, TXNPI 1508850835

Payments from drug & device makers

$4,668in general payments, 2019–2025

Across 282 payments — averaging $16.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$664
  • GSK$471
  • AbbVie$406
  • Novo Nordisk$403
  • Boehringer Ingelheim$367
  • Merck$274
  • plus $2K from 27 others

What the payments were for

  • Food & beverage$4,58398%
  • Education$852%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,668 in reported general payments places this provider in the 85th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$55,316
Medicare patients
116
Services billed
583

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide152$194,472
JanuviaSitagliptin Phosphate84$108,747
JardianceEmpagliflozin61$82,922
FarxigaDapagliflozin Propanediol50$73,004
TrulicityDulaglutide32$50,379
JanumetSitagliptin Phos/Metformin Hcl24$36,582
LinzessLinaclotide43$33,053
MounjaroTirzepatide21$29,518
RybelsusSemaglutide14$18,227
TradjentaLinagliptin16$16,409
MyrbetriqMirabegron23$15,479
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog24$14,510
XareltoRivaroxaban13$11,714
Lantus SolostarInsulin Glargine,hum.Rec.Anlog50$11,220
EliquisApixaban14$9,507

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$403$212,700166 claims
MerckJanuvia, Janumet$274$145,330108 claims
Boehringer IngelheimJardiance, Tradjenta$367$99,33177 claims
Lilly USA, LLCTrulicity, Mounjaro$664$79,89653 claims
AstraZenecaFarxiga$270$73,00450 claims
AbbVieLinzess, Creon$406$35,31056 claims
PfizerEliquis, Premarin$100$17,50533 claims
Astellas Pharma US IncMyrbetriq$145$15,47923 claims
Johnson & JohnsonXarelto$103$11,71413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Laredo

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →